Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

No abstract is available for this paper.

• Publication year

  1998

• Venue

  British Journal of Psychiatry

• Publication date

  1998-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1192/bjp.172.6.499PMID 9828990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

  1997cited by this paper
• Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.

  1997cited by this paper
• Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

  1997cited by this paper
• Olanzapine versus Placebo and Haloperidol

  1996cited by this paper
• Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

  1996cited by this paper
• Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

  1996cited by this paper
• Neuroleptic withdrawal in schizophrenic patients.

  1995cited by this paper
• Neuroleptic withdrawal in schizophrenic patients. A review of the literature.

  1995cited by this paper
• Dose response of prophylactic antipsychotics.

  1993cited by this paper
• Intermittent versus maintenance neuroleptic long-term treatment in Schizophrenia—2-year results of a German multicenter study

  1993cited by this paper
• Psychopharmacologic treatment of schizophrenia.

  1993cited by this paper
• A note on randomization and selection bias in maintenance therapy clinical trials.

  1991cited by this paper
• Methodologic issues in maintenance therapy clinical trials.

  1991cited by this paper
• Intermittent vs maintenance medication in schizophrenia. Two-year results.

  1991cited by this paper
• A note on randomization and selection bias in maintenance therapy clinical trials.

  1991cited by this paper
• Continuous versus targeted medication in schizophrenic outpatients: outcome results.

  1990cited by this paper
• Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year.

  1989cited by this paper
• Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.

  1988cited by this paper
• Double-Blind Comparison of Half-Dose and Standard-Dose Flupenthixol Decanoate in the Maintenance Treatment of Stabilised Out-Patients with Schizophrenia

  1987cited by this paper
• Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.

  1987cited by this paper
• II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment

  1986cited by this paper
• Costs and benefits of two doses of fluphenazine.

  1984cited by this paper
• Low dose medication strategies in the maintenance treatment of schizophrenia.

  1983cited by this paper
• Drug and family therapy in the aftercare of acute schizophrenics.

  1978cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper

• Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders.

  2024cites this paper
• Effects of Age and Anxiety on Short-Term Rehospitalization Rates in Japanese Patients with Schizophrenia

  2020cites this paper
• Effects of olanzapine on anxiety-related behaviour in male and female rats assessed after 21-24 and 42-45 days of chronic treatment.

  2020cites this paper
• NDT_A_209284 2559..2569

  2019cites this paper
• A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

  2019cites this paper
• The Black Book of Psychotropic Dosing and Monitoring.

  2018cites this paper
• Antipsychotic treatment and psychosocial functioning in schizophrenia – results from Romanian cohort of EUFEST study

  2016cites this paper
• Comparative Effectiveness of Blonanserin and Paliperidone in 93 In-patients with Acute- to Maintenance-phase Schizophrenia

  2016cites this paper
• Modelling the Treated Course of Schizophrenia: Development of a Discrete Event Simulation Model

  2015cites this paper
• DEVELOPMENT AND COMPARATIVE EVALUATION OF CONTROLLED RELEASE TABLETS vs. CONVENTIONAL TABLETS OF OLANZAPINE AND PROCHLORPERAZINE FOR CLINICAL SAFETY AND THERAPEUTIC EFFICACY

  2014cites this paper
• Oral olanzapine: a guide to its use in adults with schizophrenia or bipolar I disorder

  2013cites this paper
• Oral olanzapine: a guide to its use in adults with schizophrenia or bipolar I disorder

  2013cites this paper
• Costo-efficacia di risperidone iniettabile a rilascio prolungato nel trattamento della schizofrenia in Italia

  2013cites this paper
• Antipsychotic agents: efficacy and safety in schizophrenia

  2012cites this paper
• Antipsychotic drug treatment for elderly people with late-onset schizophrenia.

  2012cites this paper
• Comparison of Long-Term (At Least 24 Weeks) Weight Gain and Metabolic Changes Between Adolescents and Adults Treated with Olanzapine

  2012cites this paper
• Modelling the treated course of schizophrenia: Development of a discrete event simulation model

  2012cites this paper
• Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

  2012cites this paper
• Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia.

  2012cites this paper
• Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia

  2011cites this paper
• Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics

  2011cites this paper
• Quantifying clinical relevance in the treatment of schizophrenia.

  2011cites this paper
• SVEUILIŠTE U ZAGREBU MEDICINSKI FAKULTET

  2010cites this paper
• Dopamine Receptors and the Treatment of Schizophrenia

  2010cites this paper
• Belgian Schizophrenia Outcome Survey – Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol

  2009cites this paper
• Effectiveness of brief cognitive-behavioral therapy for schizophrenia delivered by mental health nurses: relapse and recovery at 24 months.

  2009cites this paper
• The Cost of Relapse in Schizophrenia and Schizoaffective Disorder

  2009cites this paper
• Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features.

  2009cites this paper
• How to read and understand and use systematic reviews and meta‐analyses

  2009influential citation
• [Antipsychotics and pregnancy: a clinical case].

  2009cites this paper
• An evidence-based strategy for remission in schizophrenia.

  2008cites this paper
• Effectiveness and Tolerability of Olanzapine in the Treatment of Adolescents with Schizophrenia and Related Psychotic Disorders: Results from a Large, Prospective, Open-Label Study

  2008cites this paper
• Factors Affecting Time to Rehospitalization in Han Chinese Patients With Schizophrenic Disorder in Taiwan

  2008cites this paper
• Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study.

  2008cites this paper
• Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study.

  2008cites this paper
• Olanzapin

  2008cites this paper
• Frequency and effects of psychosocial interventions additional to olanzapine treatment in routine care of schizophrenic patients

  2008cites this paper
• Cost‐effectiveness of antipsychotics for outpatients with chronic schizophrenia

  2007cites this paper
• All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics: An Integrated Analysis

  2007cites this paper
• Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.

  2007cites this paper
• Pharmacotherapy of Schizophrenia

  2007cites this paper
• Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.

  2007cites this paper
• The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.

  2007cites this paper
• New developments in the treatment of schizophrenia.

  2007cites this paper
• [Cardiac complications in patients with schizophrenic disorders].

  2007cites this paper
• Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses

  2006cites this paper
• Kardiale Komplikationen bei Patienten mit schizophrenen Störungen

  2006cites this paper
• Apport des antipsychotiques atypiques dans la prise en charge à long terme de la schizophrénie

  2006cites this paper
• A case of cutaneous vasculitis associated with olanzapine.

  2006cites this paper
• Pharmakotherapie der Schizophrenie

  2006influential citation
• Letter to the Editor

  2006cites this paper
• Synthèse à partir de cinq études sur l'efficacité et la tolérance de la rispéridone à action prolongée

  2006cites this paper
• A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany

  2006cites this paper
• Remission and relapse in psychosis: operational definitions based on case-note data

  2006cites this paper
• [The use of atypical antipsychotics in the long-term care of schizophrenia].

  2006cites this paper
• Evolution of antipsychotic intervention in the schizophrenic psychosis.

  2006cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

  2006influential citation
• [Pharmacotherapy for schizophrenia].

  2006cites this paper
• Why Do Physicians Switch From One Antipsychotic Agent to Another?: The "Physician Drug Stereotype"

  2006cites this paper
• Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

  2006cites this paper
• Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent

  2006cites this paper
• La valutazione economica del trattamento farmacologico con antipsicotici nella schizofrenia: una revisione sistematica della letteratura

  2005cites this paper
• Olanzapine for schizophrenia.

  2005cites this paper
• Seguridad y tolerabilidad de la olanzapina con otros antipsicóticos en el tratamiento de pacientes ancianos con esquizofrenia: un estudio naturalista

  2005cites this paper
• Hospitalization Rates in Patients During Long-Term Treatment With Long-Acting Risperidone Injection

  2005cites this paper
• Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.

  2005cites this paper
• Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator.

  2005cites this paper
• Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.

  2005cites this paper
• Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

  2005cites this paper
• The introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in Newfoundland and Labrador: the impact on hospital utilization by patients with schizophrenia

  2005cites this paper
• Olanzapine: a critical review of recent literature

  2005cites this paper
• Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia.

  2005cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia

  2005cites this paper
• Psychopharmakologische Langzeittherapie der Schizophrenie und die neu entwickelten Substanzen

  2004cites this paper
• Der Einsatz neuer Antipsychotika in der Langzeittherapie der Schizophrenie

  2004cites this paper
• The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.

  2004cites this paper
• A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.

  2004cites this paper
• Estimation of Antipsychotic Effects on Hospitalization Risk in a Naturalistic Study With Selection on Unobservables

  2004cites this paper
• Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns

  2004cites this paper
• Evidence-based pharmacotherapy of schizophrenia.

  2004cites this paper
• Olanzapine versus Flupenthixol in the Treatment of Inpatients with Schizophrenia: A Randomized Double-Blind Trial

  2004cites this paper
• An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.

  2004cites this paper
• Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study

  2004cites this paper
• Dropout rates with olanzapine or risperidone: a multi-centre observational study

  2004cites this paper
• [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].

  2004cites this paper
• Schizophrenia and obesity: impact of antipsychotic medications.

  2004cites this paper
• Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.

  2004cites this paper
• Healthcare resource utilization during 1‐year treatment with long‐acting, injectable risperidone

  2004cites this paper
• Open study evaluating the onset of antipsychotic action of olanzapine in the treatment of patients with schizophrenia, schizophreniform or schizo-affective disorder

  2004cites this paper
• Course and Long-Term Treatment of Schizophrenic Psychoses

  2004cites this paper
• Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.

  2004cites this paper
• Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial.

  2004cites this paper
• Novel Antipsychotics in the Long-term Treatment of Schizophrenia

  2004cites this paper
• LONG-TERM EFFECTIVENESS OF ANTIPSYCHOTIC THERAPIES: CLINICAL CONSIDERATIONS

  2004cites this paper
• Olanzapine for schizophrenia.

  2003cites this paper
• The new and evolving pharmacotherapy of schizophrenia.

  2003cites this paper
• 207 Novi antipsihotici New Antipsychotics

  2003cites this paper
• Impact of Side-Effects of Atypical Antipsychotics on Non-Compliance, Relapse and Cost

  2003cites this paper
• Clinical Trial Response and Dropout Rates with Olanzapine versus Risperidone

  2003cites this paper
• The efficacy of atypical antipsychotics in bipolar disorders.

  2003cites this paper